Skip to content
lifestyle.thedishh.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Insilico Medicine
Insilico Medicine and Qilu Pharmaceutical Reach Near $120 Million Drug Development Collaboration to Accelerate Novel Cardiometabolic Therapies
February 25, 2026
Insilico Medicine Nominates ISM5059, the Peripheral-restricted NLRP3 Inhibitor as Preclinical Candidate, for the Treatment of Multiple Inflammatory and Metabolism Indications
February 7, 2026
Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501
February 7, 2026
←
Previous Page
1
2
3